Vanda Pharmaceuticals Inc.

VNDA

US9216591084

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/09/2024 BST			5-day change	1st Jan Change
4.980 ^USD	-0.80%		-1.97%	+18.01%

07-31	Transcript : Vanda Pharmaceuticals Inc., Q2 2024 Earnings Call, Jul 31, 2024
07-31	Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q2 Revenue $50.5M, vs. Street Est of $47.9M	MT

Presentation Operator MessageOperator (Operator)Thank you for standing by. My name is Meg, and...

This article is reserved for subscribers

Signed up already?

Not subscribed yet?

Latest news about Vanda Pharmaceuticals Inc.

Transcript : Vanda Pharmaceuticals Inc., Q2 2024 Earnings Call, Jul 31, 2024	07-31
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q2 Revenue $50.5M, vs. Street Est of $47.9M	07-31	MT
Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024	07-31	CI
Vanda Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07-31	CI
Cantor Fitzgerald Initiates Vanda Pharmaceuticals at Overweight With $11 Price Target	07-11	MT
Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz	07-01	MT
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index	06-30	CI
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Defensive Index	06-30	CI
The same old winners	06-27
Future Pak withdraws offer to buy Vanda Pharmaceuticals	06-26	RE
Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc., Butler Hall Capital LLC, Shareholder Capital LLC and others.	06-25	CI
Vanda rejects Future Pak and Cycle Pharma's takeover offers	06-20	RE
Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc..	06-18	CI
Sector Update: Health Care Stocks Ease Late Afternoon	06-13	MT
Sector Update: Health Care Stocks Softer Thursday Afternoon	06-13	MT
Sector Update: Health Care	06-13	MT
Vanda Pharmaceuticals Receives Revised Offer From Future Pak; Shares Rise	06-13	MT
Future Pak raises cash portion of buyout offer for Vanda	06-13	RE
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	06-06	MT
Sector Update: Health Care Stocks Advance Thursday Afternoon	06-06	MT
Sector Update: Health Care	06-06	MT
Vanda Pharmaceuticals' Shares Rally After Company Receives $466 Million Buyout Offer From Cycle Pharma	06-06	MT
Cycle Pharmaceuticals Offers to Buy Vanda Pharmaceuticals for $466 Million	06-06	MT
Top Premarket Gainers	06-06	MT
Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. for approximately $490 million.	06-05	CI

Chart Vanda Pharmaceuticals Inc.

Duration

Period

More charts

Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Companyâs commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).

Employees

203

Sector

Biotechnology & Medical Research

Calendar

29/10/2024 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company